A carregar...
Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
Incretin based therapies have been introduced into the treatment options of type 2 diabetes a few years ago. Among them, the orally active DPP-4 inhibitors have established themselves as insulinotropic agents. Their advantage is the glucose-dependent insulinotropic action without an intrinsic risk f...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Libertas Academica
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3411498/ https://ncbi.nlm.nih.gov/pubmed/22879795 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMED.S7274 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|